All Stories

  1. Protein Kinase Expression of the AKT/mTOR Signaling Pathway in Peripheral Mononuclear Cells of Schizophrenia Patients: A Pilot Study
  2. Myeloperoxidase, Cathepsin D, and Plasminogen Activation Inhibitor Type 1 as Potential Biomarkers of Schizophrenia (pilot study)
  3. Positive and Negative Symptoms of Schizophrenia and Polymorphic Variants of the TCF4 Gene: Pilot Associative Study
  4. Регуляторный потенциал полиморфных вариантов генов BDNF-опосредованных протеинкиназных сигнальных путей, ассоциированных с шизофренией
  5. Polymorphic Variants of Neurotrophic Factor Genes in Affective Disorders: Pilot Study
  6. Neuroinflammation in Schizophrenia: An Overview of Evidence and Implications for Pathophysiology
  7. Polymorphic variant of NQO1 rs1800566 and antipsychotic-induced metabolic disorders in patients with schizophrenia
  8. Academic Psychiatric School in Siberia: History of Formation and Horizons of Development. Interview with an Academician of RAS Nikolay A. Bokhan
  9. The Effect of Metabolic Syndrome and its Individual Components on the Duration of the QTc Interval in Different Gene Carriers of the Nitric Oxide Synthase 1 Adapter Protein Gene in Patients with Schizophrenia
  10. The Role of GST Gene Polymorphic Variants in Antipsychotic-Induced Metabolic Disorders in Schizophrenia: A Pilot Study
  11. Neuroinflammatory and neurodegenerative aspects of Parkinson’s disease
  12. The association of NOS1AP gene polymorphisms with the duration of the QT interval in patients with schizophrenia receiving antipsychotic therapy
  13. Прогнозирование эффективности фармакотерапии у больных депрессивными расстройствами на основе генетических показателей
  14. Blood Growth Factor Levels in Patients with Systemic Lupus Erythematosus: High Neuregulin-1 is Associated with Comorbid Cardiovascular Pathology
  15. Взаимосвязь тромбоцитарных факторов роста с клиническими и клинико-динамическими характеристиками у пациентов с аффективными расстройствами
  16. Comparative analysis of EEG in patients with schizophrenia receiving various atypical antipsychotics
  17. Ассоциативный анализ гаплотипов и регуляторный потенциал генов серотониновых рецепторов у больных шизофренией с тардивной дискинезией
  18. NOS1AP Gene Variants and Their Role in Metabolic Syndrome: A Study of Patients with Schizophrenia
  19. Untargeted Plasma Metabolomic Profiling in Patients with Depressive Disorders: A Preliminary Study
  20. Associations between components of metabolic syndrome and cognitive impairment in patients with schizophrenia
  21. Associations of serum neuromarkers with clinical features of Parkinson’s disease
  22. Serum neurofilament light chains in assessing the course of multiple sclerosis
  23. The relationship between the rs6265 polymorphism of the BDNF gene and the level of serum neurotrophic factor in patients with Parkinson’s disease
  24. Association of inflammation and chronic fatigue syndrome in patients with Parkinson’s disease
  25. Growth factors PDGF-AA, PDGF-BB and BDNF as potential differentiating biomarkers of unipolar and bipolar depression
  26. A pilot study of associations of markers of glial and neuronal degeneration with executive functions in alcohol use disorders
  27. Serum neurofilaments light chain as a diagnostic marker of multiple sclerosis
  28. Differential Expression of Proteins Associated with Bipolar Disorder as Identified Using the PeptideShaker Software
  29. Relationship of Neurospecific Serum Proteins with Clinical Features in Depressive Episode and Recurrent Depressive Disorder
  30. Serum Levels of S100B Protein and Myelin Basic Protein as a Potential Biomarkers of Recurrent Depressive Disorders
  31. Association of Single Nucleotide Polymorphisms of Cytokine Genes with Depression, Schizophrenia and Bipolar Disorder
  32. Building Predictive Models for Schizophrenia Diagnosis with Peripheral Inflammatory Biomarkers
  33. EEG Frontal Asymmetry in Unipolar and Bipolar Depression
  34. Association of Peripheral Inflammatory Biomarkers and Growth Factors Levels with Sex, Therapy and Other Clinical Factors in Schizophrenia and Patient Stratification Based on These Data
  35. Роль полиморфизма генов дофаминовой и глутаматной систем в клинической гетерогенности шизофрении и развитии антипсихотик-индуцированных побочных эффектов
  36. The Influence of Antipsychotic Treatment on the Activity of Abzymes Targeting Myelin and Levels of Inflammation Markers in Patients with Schizophrenia
  37. Serum Growth Factors in Schizophrenia Patients
  38. In vitro effect of serum IgGs with oxidoreductase activities of schizophrenic patients on apoptosis level
  39. Cell Adhesion Molecules in Schizophrenia Patients with Metabolic Syndrome
  40. The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia
  41. Chemokine Dysregulation and Neuroinflammation in Schizophrenia: A Systematic Review
  42. Coherence of the electroencephalogram and peripheral markers of nerve tissue damage in depressive disorders
  43. BDNF gene RS6265 polymorphism in patients with multiple sclerosis of Tomsk region
  44. Cytokines as Potential Biomarkers of Clinical Characteristics of Schizophrenia
  45. Multiplex Analysis of Serum Cytokine Profiles in Systemic Lupus Erythematosus and Multiple Sclerosis
  46. Executive dysfunction in affective disorders: differences in bipolar affective disorder and depressive episode
  47. Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome
  48. Levels of Acylcarnitines and Branched-Chain Amino Acids in Antipsychotic-Treated Patients with Paranoid Schizophrenia with Metabolic Syndrome
  49. Immunoglobulins G of Patients with Schizophrenia Protects from Superoxide: Pilot Results
  50. Cytokine level in patients with mood disorder, alcohol use disorder and their comorbidity
  51. The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
  52. Catalytic Antibodies in Bipolar Disorder: Serum IgGs Hydrolyze Myelin Basic Protein
  53. Serum Cytokine Levels of Systemic Lupus Erythematosus Patients in the Presence of Concomitant Cardiovascular Diseases
  54. Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia
  55. Circuits regulating pleasure and happiness – focus on potential biomarkers for circuitry including the habenuloid complex
  56. Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome
  57. Возможные нейрофизиологические маркеры для дифференциальной диагностики биполярных и униполярных аффективных расстройств
  58. Оценка цитотоксических эффектов IgG, выделенных из сыворотки крови больных шизофренией
  59. Molecular genetic study of clinical and cognitive features of schizophrenia: No associations with genes SOD2, GSTO1, NQO1
  60. Anhedonia as target symptom in personalized therapy of patients with mood disorders and alcohol use disorder comorbidity
  61. Current methods for predicting therapeutic response in patients with depressive disorders
  62. Correlations between clinical features of bipolar affective disorder and serum concentrations of ANKRD12 gene product, coagulation factor XIII, and cadherin 5
  63. Metabolic Syndrome in a Population of In-Patients with Schizophrenia in the Western Siberia
  64. A New Paradigm to Indicate Antidepressant Treatments
  65. Beta-Endorphin and Oxytocin in Patients with Alcohol Use Disorder and Comorbid Depression
  66. Assessment of serum BDNF levels in complex rehabilitation of patients with ischemic stroke using traditional approaches to the restoration of motor functions
  67. Association of PIP4K2A Polymorphisms with Alcohol Use Disorder
  68. Влияние органических солей лития на содержание белков Akt/mTOR-сигнального пути в мононуклеарах периферической крови больных биполярным аффективным расстройством
  69. Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms
  70. Clinical Evaluation of Different Treatment Strategies for Motor Recovery in Poststroke Rehabilitation during the First 90 Days
  71. Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action
  72. Global hypomyelination of the brain white and gray matter in schizophrenia: quantitative imaging using macromolecular proton fraction
  73. Electroencephalographic Markers of Depressive Disorders Resistance to Pharmacotherapy and Determination of a Possible Approach to Individual Prognosis of Therapy Effectiveness
  74. Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
  75. Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
  76. Features of brain activity in alcohol dependence in the task of inhibitory control
  77. Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study
  78. Cognitive impairment in patients after COVID-19
  79. Влияние когнитивных функций на уровень суицидального риска у больных шизофренией
  80. Using the quantitative EEG method in predicting the response to treatment of affective disorders
  81. Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia
  82. Модель прогнозирования метаболического синдрома у больных параноидной шизофренией
  83. Cognitive Changes in Comorbidity Alcohol Dependence and Affective Disorders
  84. Glutamate Level’s in Blood Serum of Patients with Schisophrenic Spectrum and Bipolar Affective Disorder
  85. Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome
  86. Serum BDNF’s Role as a Biomarker for Motor Training in the Context of AR-Based Rehabilitation after Ischemic Stroke
  87. Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia
  88. Association of ANKK1 polymorphism with antipsychotic‐induced hyperprolactinemia
  89. Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia
  90. Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects
  91. Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients
  92. IgG-Dependent Dismutation of Superoxide in Patients with Different Types of Multiple Sclerosis and Healthy Subjects
  93. Amino acids and acylcarnitines as potential metabolomic markers of schizophrenia: new approaches to diagnostics and therapy
  94. Clinical and laboratory assessment of the effectiveness of early rehabilitation of patients with stroke using assistive robotic tools
  95. Relationship of cognitive disorders with clinical features of alcohol dependence
  96. Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression
  97. Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients
  98. Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome
  99. Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia
  100. Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia
  101. Суицидальное поведение больных шизофренией с метаболическим синдромом
  102. Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
  103. The difference in serum proteomes in schizophrenia and bipolar disorder
  104. Association of Polymorphic Variants of Brain-Derived Neurotrophic Factor Gene (Bdnf Rs6265) and Glutamate Transporter Gene of the Second Type (Slc1a2 Rs4354668) with the Course of Multiple Sclerosis in Patients Living in Tomsk Region
  105. A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
  106. Consider Role of Glutamatergic Habenula-projecting Globus Pallidus in OCD
  107. Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium
  108. Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors
  109. SIRT1 Allele Frequencies in Depressed Patients of European Descent in Russia
  110. Disorders of spatial working memory in affective disorders with mild current depression and their neurophysiological correlates
  111. No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia
  112. Brain pathology in schizophrenia: association with clinical and constitutional factors
  113. NEUROPHYSIOLOGICAL FEATURES OF PATIENTS WITH DIFFERENT RATES OF ALCOHOL DEPENDENCE DEVELOPMENT
  114. Stress hormones in men whose professional activities are either office-based or of an extreme emergency nature
  115. Morphophenotypic predictor of the development of visceral obesity in patients with schizophrenia receiving antipsychotic therapy
  116. Суицидальное поведение больных биполярным аффективным расстройством при коморбидных психических заболеваниях
  117. The evolutionary old forebrain as site of action to develop new psychotropic drugs
  118. IgG antibodies from the sera of patients degrade myelin basic protein
  119. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia
  120. Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning
  121. The functional variant rs334558 of GSK3B is associated with remission in patients with depressive disorders
  122. Parkinson's disease and polymorphisms of the glutamatergic system genes GRIN2A, SLC1A2, and GRIK4
  123. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and metabolic syndrome in healthy subjects and schizophrenia patients
  124. Blood-Derived RNA- and microRNA-Hydrolyzing IgG Antibodies in Schizophrenia Patients
  125. Hydrolysis by catalytic IgGs of microRNA specific for patients with schizophrenia
  126. Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine
  127. Commentary on “A non-reward attractor theory of depression”: A proposal to include the habenula connection
  128. How brain mechanism of feeling pleasure and happiness evolved during the last 560 million years.
  129. Catalase activity of IgG antibodies from the sera of healthy donors and patients with schizophrenia
  130. The role of the habenula in the transition from reward to misery in substance use and mood disorders
  131. Circuits regulating pleasure and happiness: evolution and role in mental disorders
  132. Neurohumoral markers that predict the efficiency of pharmacologic therapy of depressive disorders
  133. Prolactin gene polymorphism (− 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics
  134. Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders
  135. Association of polymorphic variants of PIP5K2A and HTR2C genes with response to antidepressant therapy of patients with a current depressive episode
  136. Association study of genetic markers of schizophrenia and its cognitive endophenotypes
  137. Indices of the antioxidant system and dopamine in blood plasma in the dynamics of microwave resonance therapy in patients with alcoholism
  138. Circuits Regulating Pleasure and Happiness in Bipolar Disorder
  139. Circuits Regulating Pleasure and Happiness in Schizophrenia: The Neurobiological Mechanism of Delusions
  140. Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations
  141. Circuits Regulating Pleasure and Happiness: The Evolution of the Amygdalar-Hippocampal-Habenular Connectivity in Vertebrates
  142. Circuits Regulating Pleasure and Happiness—Mechanisms of Depression
  143. Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia
  144. Circuits Regulating Pleasure and Happiness: A Focus on Addiction, Beyond the Ventral Striatum
  145. CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects
  146. Circuits regulating pleasure and happiness in major depression
  147. Antioxidant and Immunotropic Properties of some Lithium Salts
  148. Use of Carnosine for Oxidative Stress Reduction in Different Pathologies
  149. Antibodies to native and denatured DNA in the serum of patients with schizophrenia depending on the clinical features of the disease
  150. The association of the DRD3 gene with Parkinson’s disease
  151. Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding
  152. An association of AKT1 gene polymorphism with antidepressant treatment response
  153. Serum Glutathione in Patients with Schizophrenia in Dynamics of Antipsychotic Therapy
  154. Circuits regulating pleasure and happiness: the evolution of reward-seeking and misery-fleeing behavioral mechanisms in vertebrates
  155. DNA-hydrolysing activity of IgG antibodies from the sera of patients with schizophrenia
  156. Characteristics of membrane-bound pool of leukocyte lactate dehydrogenase in healthy men of different age
  157. Serum Levels of Neurosteroids in Patients with Affective Disorders
  158. Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility
  159. Association Study Indicates a Protective Role of Phosphatidylinositol-4-Phosphate-5-Kinase against Tardive Dyskinesia
  160. Proteins of the Akt1/GSK-3β signaling pathway in peripheral blood mononuclear cells of patients with affective disorders
  161. Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia
  162. Glutamate Concentration in the Serum of Patients with Schizophrenia
  163. Glucose-6-phosphate dehydrogenase and catalase activities in erythrocytes of schizophrenic patients under pharmacotherapy with traditional antipsychotics
  164. Effects of Neuroprotector Cortexin on the Dynamics of Neuroendocrine System Parameters in Patients with Organic Emotionally Labile (Asthenic) Disorders
  165. New insights into the mechanism of drug-induced dyskinesia
  166. Conformational Stability of Leukocyte Lactate Dehydrogenase in Healthy Men of Different Age
  167. Neurosteroids Dehydroepiandrosterone and Its Sulfate in Individuals with Personality Disorders Convicted of Serious Violent Crimes
  168. Effects of dehydroepiandrosterone sulfate on induced apoptosis of lymphocytes in healthy persons
  169. Study of the indices of antioxidant defense in mental maladaptation
  170. No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia
  171. NMDA receptor genotypes associated with the vulnerability to develop dyskinesia
  172. The correlation between schizophrenia duration and the serum concentration of dehydroepiandrosterone sulfate
  173. The state of the antioxidant system during therapy of patients with multiple sclerosis
  174. Spontaneous and In Vitro Induced Apoptosis of Lymphocytes and Neutrophils in Patients with Alcohol Dependence
  175. Missense polymorphisms in three oxidative-stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia
  176. PIP5K2A-dependent regulation of excitatory amino acid transporter EAAT3
  177. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia
  178. P.3.c.044 Tardive dyskinesia and polymorphism of dopamine D3, serotonin 2A and 2C receptors in Russian psychiatric inpatients
  179. P.3.d.010 Catabolic-anabolic balance and leucocytes's apoptosis in patients with schizophrenia
  180. P.2.b.011 Antidepressant therapy and apoptosis of immnocompetent cells in patients with depressive disorders
  181. P.3.c.017 Influence of atypical neuroleptic quetiapine on the serum dehydroepiandrosterone/ cortisol ratio in schizophrenia
  182. Signs of apoptosis of immunocompetent cells in patients with depression
  183. P.6.063 Clinical and biological effectiveness of anar therapy in opiate addicts
  184. P.1.045 Psychotropic drugs and homeostatic systems: Mechanism of psychoneuroimmunomodulation
  185. P.2.016 Influence of atypical neuroleptic on cell apoptosis in patients with schizophrenia in the course of the therapy
  186. P.1.107 Influence of pharmacotherapy on fas-receptorsand spontaneous apoptosis of lymphocytes in patients with depressive disorders
  187. Immunity system in alcoholism